3 unknown, 1 terminated. 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Terminated 1 |
| Early Phase 1 | 1 | Unknown 1 |
Follow Henrik Gregersen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clarithromycin in Multiple Myeloma Induction Therapy Clarithromycin, Placebo, VCD induction therapy - Multiple Myeloma | Phase 2 | Terminated | Henrik Gregersen | 58 | 2015-01-01 | 2016-09-20 |
| Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan, Carfilzomib/dexamethasone maintenance, Observation without carfilzomib/dexamethasone maintenance - Multiple Myeloma | Phase 2 | Unknown | Henrik Gregersen | 200 | 2015-01-01 | 2018-08-17 |
| Microdose Study of Melphalan, Bortezomib and Dexamethasone Melphalan, Bortezomib, Dexamethasone - Multiple Myeloma | Early Phase 1 | Unknown | Henrik Gregersen | 6 | 2014-01-01 | 2015-12-08 |
| Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma Standard myeloma treatment, Clarithromycin, Sulfamethoxazole/trimethoprim - Multiple Myeloma, Infection | Phase 2 | Unknown | Henrik Gregersen | 300 | 2013-01-01 | 2015-12-08 |
Multiple Myeloma (4) · Infections (1) · Recurrence (1)
Clarithromycin (2) · Observation (2) · Bortezomib (1) · Dexamethasone (1) · Melphalan (1) · Neoadjuvant Therapy (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · carfilzomib (1)
Denmark (4) · Finland (1) · Lithuania (1) · Norway (1) · Sweden (1)
2014 (1)